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Background: Asbestos is a first level carcinogen. However, few epidemiological studies analyse the risk and
protective factors associated with asbestos-related diseases and follow up these conditions in the general
population. Pleural mesothelioma, caused by inhalation of asbestos fibres at work, at home or in the environment,
is the most representative asbestos-related disease.
The objectives of this study are to analyse the risk and protective factors associated with asbestos-related
diseases and to investigate the incidence of new clinical manifestations in patients already diagnosed with
some form of ARD.
Methods/Design: We have designed a matched case–control study with follow up of both cohorts from a
population of a health district of the Barcelona province that has been exposed to asbestos for a period of
90 years.
Discussion: A better understanding of asbestos-related diseases should improve i) the clinical and
epidemiological follow up of patients with this condition; ii) the design of new treatment strategies; iii) and the
development of preventive activities. At the end of the study, the two cohorts created in this study (affected cases
and healthy controls) will constitute the basis for future research.
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Inhalation of asbestos fibres is detrimental to human
health. The toxicity of asbestos has been known since
the early twentieth century and linked almost exclusively
to pleural mesothelioma [1]. However, this is just one of
the 10 clinical conditions that currently define Asbestos
Related Diseases (ARD) [2].
Asbestos is a mineral whose main characteristics are
incombustibility and thermal isolation. As a result of
these properties, asbestos is used in a wide range of ap-
plications in almost every industrial sector [3,4].
Workers at fibre cement plants, painters, carriers of
asbestos materials and construction workers are the* Correspondence: mrosell.mn.ics@gencat.cat
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distribution, and reproduction in any mediumpopulation with the highest risk of exposure to asbestos
fibres [5].
ARD is a group of 10 conditions that originate from
the inhalation and subsequent deposit of asbestos fibres
in the pulmonary parenchyma and which affect mainly
the respiratory system. Following the most widely ac-
cepted guidelines [2,6], ARD are classified in two groups
(malignant and non-malignant) which include diseases
of the lung parenchyma, the pleura and the bronchi.
Asbestos toxicity is related to its fibrous structure,
since studies have demonstrated that pulverized asbestos
does not cause disease [7]. Due to individual susceptibil-
ity factors, the development of ARD cannot be ruled out
in individuals with low intensity exposure to asbestos
[8,9]. The study of risk and protective factors of ARD
can be hindered by the latency period, which can be as
prolonged as 40 years [10].Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
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cinogen. [4] The most widely accepted oncological model is
the dose–response without a safety level. [8,11] Fibrogenic
and carcinogenic properties are related, particularly in the
amphibole type of asbestos. The role of amphibole asbes-
tos as a co-carcinogenic agent has been shown in the de-
velopment of mesothelioma and in other pulmonary
neoplasms [12]. The risk of malignant mesothelioma in-
creases with age and depends on when first exposure
started. These factors are also closely associated with the
level of exposure, continuity of exposure, and latency
period [13].
The main risk factor to develop ARD is inhalation of
asbestos fibres as a result of work exposure. However,
not everybody that has been or is exposed to asbestos
develops ARD. A main difficulty in the study of ARD is
the lack of information related to exposure history in
the medical records and the lack of awareness of the
workers themselves. In addition, the late age at diagnosis
due to the time lag between exposure and clinical mani-
festations is another factor that explains the significant
number of ARD cases that are not considered a work-
related disease [14]. A large number of ARD worldwide
are still not considered or notified as a work-related dis-
ease [6].
Asbestosis, asbestos-related lung cancer and meso-
thelioma are classified in Spain as work-related diseases
in the Royal Decree 1995/1978 of 12th of May [15].
Nevertheless, the actual morbidity and mortality caused
by ARD are still largely unknown, mainly due to the
scarce notification of these cases as work-related condi-
tions [16].
Fibre inhalation when living near an asbestos source, liv-
ing together with an asbestos worker that brought asbestos
fibres in the work clothes, the domestic use of products
manufactured with asbestos and simple environmental ex-
posure constitute non-work related exposures that can
also cause ARD. The association with simple environmen-
tal exposure is better known for mesothelioma than for
asbestos-related lung cancer [17-20]. The incidence of be-
nign ARD cases that originate from environmental expos-
ure has hardly been investigated. Moreover, no data on the
incidence of additional ARD in patients already suffering
from any form of ARD exist, and no studies on the pro-
tective factors of ARD have been published.
The association of asbestos with ARD is modified by
tobacco consumption. Indeed, smokers exposed to as-
bestos are at higher risk of developing radiologic signs of
asbestosis than non-smokers [21]. Also, asbestosis itself
is a risk factor for lung cancer [12]. To date, no definite
association between tobacco consumption and meso-
thelioma has been found [4,9].
It is generally accepted that the spontaneous incidence
of mesothelioma is very rare, close to 1 new case/millioninhabitants/year [22]. However, this figure has been now
reviewed and increased to 3 new cases/million inhabi-
tants/year [7]. In the province of Barcelona, the inci-
dence of mesothelioma estimated from mortality data of
residents equals 8.3 cases/million inhabitants/year in
men, and 4.7 cases/million inhabitants/year in women.
These figures are much higher in Barcelona’s neighbouring
towns of Cerdanyola del Vallès, with 18.4 cases/million
inhabitants/year, and Ripollet, with 17.6 cases/million
inhabitants/year [23].
A recent study on all types of ARD in our area show
an incidence of 95 cases/million inhabitants/year and a
prevalence of 910 cases/million inhabitants/year; in par-
ticular, the incidence and prevalence of mesothelioma
are 30 and 10 cases/million inhabitants/year, respectively
[10]. The severity of pleural mesothelioma and the possi-
bility of an upward trend in the incidence of ARD [24]
are the leading motives for the research team to under-
take the current project, in continuity with our previous
work.
The plausibility of asbestos as the cause of ARD will
be strengthened with the case–control design of this
project. Also, the creation of two parallel cohorts for
comparison over time will constitute the basis for future
research.
Asbestos-related diseases, and non-malignant ARD
specifically, are poorly understood causes of morbidity
and mortality. Indeed, the course of these conditions in
our study population is unknown. The transition of
ARD from non-malignant to malignant has not been
elucidated, and few prospective studies that address this
question have been published [25].
Up-to-date data on the impact of asbestos exposure
on morbidity and mortality and on the risk and protect-
ive factors of the exposed general population are needed.
Our working hypothesis is that within the group of ARD
patients that develop a new ARD, a significant number
of non-malignant ARD cases will develop into malignant
ARD. The pattern of geographical distribution of new
ARD cases requires a study with a case–control design.
The experience of the research team suggests that over
75% of ARD cases are diagnosed within the primary care
network, since it is the best and most accessible gateway
to the National Health System. Thus, the primary care
network becomes a comprehensive setting to conduct
this type of study.
The analysis of mortality in ARD cases is another rele-
vant aim of this project. In addition to the difficulties in
obtaining a final certain diagnosis, ARD must compete
with other diseases as the underlying cause of death
certification.
The concordance between the underlying cause of
death in the Statistical Bulletin and final hospital dis-
charge records is a fundamental quality measurement of
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within the National Health System is an essential re-
search area. However, in our setting it is as yet under-
developed for primary care [27], particularly in relation
to ARD. We therefore aim to analyze the impact of ARD
on health services through direct costs (financial burden
for high cost health conditions) using the prevalence
method, together with burden of disease, which com-
bines mortality with health outcomes [28].
Hypotheses
The study of risk and protective factors associated with
ARD, new ARD in patients with one or more previous
diagnosis of ARD (additional ARD) and the space-time
clustering of ARD patients in specific geographical areas
generate the following working hypotheses:
1. Lifestyles and individual susceptibility influence the
course of asbestos-related diseases.
2. Clinical parameters will change in 50% ARD patients
every year, and for the three years of duration of the
study.
3. 10% of patients diagnosed with one or more ARD
will present some new ARD (additional ARD) during
the three years of the study.
4. Environmental exposure determines the
geographical clusters of ARD cases in the study
area.
5. The protocolized follow up of all ARD patients
facilitates the management of the disease and
decreases the health expense allocated to ARD
(burden and costs of the disease).
6. ARD as the underlying cause of death certification
coincides with the mortality found in the population
of the study area.
Objectives
Main objective
The main objective of this project is the identification of
protective and risk factors associated with new cases of
ARD and with additional ARD, and to characterise ARD’s
geographical clustering.
Specific objectives
– To identify the lifestyles and associated morbidity
that might determine ARD incidence.
– To quantify the proportion of ARD cases which
present changes in the clinical parameters on a
yearly basis during the three years of duration of the
study.
– To quantify the proportion of ARD cases that
present an additional ARD during the three years of
duration of the study.– To describe the geographical clustering of ARD
cases in the study area, determined by exposure
factors and individual susceptibility.
– To analyze the effectiveness of the management and
control of ARD through a specific protocol and its
impact in the reduction of the health budget
allocated to ARD (burden and costs of ARD).
– Finally, to describe the level of agreement between
ARD as the underlying cause of death stated in
death certificates and final hospital discharge
records.
Methods/Design
1. Study area: health district with the 5 towns in the
Barcelona province with the highest morbidity and
mortality caused by asbestos [10]: Cerdanyola del
Vallès, Ripollet, Barberà del Vallès, Badia del Vallès
and Montcada i Reixac. All these towns refer the
ARD patients to the only hospital that participates
in this project (Hospital Parc Taulí).
2. Study population: all inhabitants (approximately
174,515 [29]) of the study area that consent to
participate in the study.
3. Study network setting: all Catalan Health Institute
Primary Health Care Teams (PHCT) in the 5 above
mentioned towns. They all use the same
classification of disease (ICD-10) and the same
referral hospital. In total, this health services
network provides health care for 174,515 people.
4. Design: community study of ARD incident cases
and matched controls (1:1), with yearly, protocolized
follow up of ARD cases and healthy controls.
5. ARD definition: ARD is a group of 10 conditions
that affect mainly the respiratory system, caused by
the inhalation and subsequent deposit of asbestos
fibres. Following the most widely accepted guidelines
[2], ARD are classified into malignant (pleural
mesothelioma, peritoneal mesothelioma, asbestos-
related bronchopulmonary carcinoma, and other
rare neoplasms) and non-malignant, which comprise
diseases of the lung parenchyma (asbestosis or
interstitial lung fibrosis), of the pleura (isolated
pleural plaques, diffuse pleural fibrosis or pleural
thickening and benign pleural effusion), and of the
bronchi (chronic bronchial obstruction and rounded
atelectasis).
6. Definition of ARD case: cases are defined as any
person within the study area diagnosed with at least
one ARD between 1/1/2011 and 31/12/2013, in
agreement with the diagnostic criteria internationally
accepted [2]. All participants must sign the informed
consent form. For the diagnosis of ARD, the
fulfilling of the three following conditions is
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pathology techniques such as the presence of
asbestos bodies in the bronchoalveolar lavage or in a
cytology sample must show that the patient has a
lesion compatible with ARD in the respiratory
system; b) sufficient time elapsed between work and/
or environmental asbestos exposure; c) and
exclusion of other possible causes.
7. Definition of control: when a patient is diagnosed
with ARD, he/she will be assigned a matched
control according to the following criteria: no ARD
diagnosis, same age (±5 years), same gender, same
town with same period of residence (exposure), and
accepts the ethical requirements of the study. The
controls that become a case during the study period
will be followed up and analysed in depth.
8. Study variables:
Essential variables:
a) ARD diagnosis (10 conditions): interstitial lung
fibrosis, isolated pleural plaques, diffuse pleural
fibrosis, benign pleural effusion, chronic
bronchial obstruction, rounded atelectasis,
pleural mesothelioma, peritoneal mesothelioma,
asbestos-related pulmonary carcinoma and other
neoplasms.
b) Clinical course: stable, worsening, detection of new
ARD, change in disease progression phase, death.
Socio-demographic variables: gender (female = 1,
male = 0), age, place of birth and current place of
residence.
Exposure variables: source (asbestos factory, other
related businesses, living near an asbestos source,
living with an asbestos worker and unknown) and
exposure times.
Clinical variables: tobacco consumption (non
smoker/smoker/ex-smoker); cigarettes/year; pack-
years of smoking; years since quitting for ex-
smokers; comorbidity, i.e., polymorbidity and
current medication classified by organic systems –
cardiovascular, respiratory, digestive, nephro-
urologic, dermatological, musculoskeletal, nervous
and oncologic; and variables related to physical
activity in adults [30,31].
ARD follow up variables:
a) Clinical symptoms: asymptomatic; persistent dry
cough; respiratory failure symptoms; oncologic
symptoms; other.
b) Clinical signs: digital clubbing, crackles.
c) Imaging signs: pleural plaques; thickening of the
pleura; rounded atelectasis; pulmonary fibrosis;
partial pleural effusion; massive pleural effusion.
Diagnostic variables: imaging (X-ray, conventional
and high-resolution computed axial tomography,
magnetic resonance imaging, ultrasound); pathology(biopsy, cytology, autopsy); respiratory function tests
(spirometry, gas exchange).
Variables of health resources utilization: visits to the
family doctors and specialists and scheduled and
unscheduled hospital admissions, per year and due
to any disease.
9. Circuit for cases and follow up: each Primary
Health Care Team (PHCT) has a study assigned
physician with an interest in ARD that will be
responsible for the protocolized follow up of each
case. There will be a first visit in the practice
followed by two contacts, usually via telephone
interview. The family doctor that diagnoses the
patient refers him/her to the respiratory medicine
specialist for confirmation, then includes all this
information in the electronic medical record and
notifies the assigned physician, who will then
interview the patient and if he/she is eligible, the
study assigned physician will explain the study and
invite him/her to participate. If the patient accepts,
he/she must sign the informed consent form and
will be included in the study.
10.Circuit for controls and follow up: controls will be
selected randomly, based on each case’s
characteristics and with the assistance of a health
information system. If the control selected cannot be
reached or refuses to participate, the next person in
the list according to a table of random numbers will
be contacted.
11.Level of detection of cases: a major challenge of
this study is the comprehensive detection of incident
cases, which will be obtained through the
optimisation of the circuits described in sections 9
and 10. To this end, the ability of the research team
to train and raise awareness among the colleagues in
primary care in ARD detection is considered
essential. A minimum of one session per year will
take place for the three years of duration of the
project, to train and involve the professionals of the
primary care teams of the study area.
Videoconferences can also be used. The research
team will identify new cases from the hospital
register.
12.Estimated number of new cases detected and of
controls: according to previous data from the
current study area [10], 17 new cases (51 during the
three year study period) will be detected annually
amongst this population of 174,515 inhabitants.
13.Collected data entry in a single database: data will
be automatically entered using a bar code reader. A
hard-copy of every file will be stored for future
checks, together with the informed consent form.
14.Statistical analysis: a descriptive analysis of the
variables will be carried out. The differences
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test, Student’s t-test, ANOVA or the corresponding
non-parametric tests. The crude association between
dependent and independent variables will be
analysed using the Mantel-Haenszel’s matched odds
ratio. Conditional logistic regression will be used to
calculate the adjusted odds ratio. For the survival
analysis of the follow up of the cohort Cox
regression will be used, and the hazard ratios will be
calculated. Mortality underreporting will be
calculated through the analysis of the death bulletins
for the patients affected by ARD who die as a result
of any of the 10 ARD conditions during follow up.
Principal Component Analysis will be used for the
analysis of geographical clusters. For the economic
evaluation, regression methods will be used taking
into account direct costs (health resources utilized),
indirect costs (production lost) and burden of
disease (mortality and objective and perceived health
status). The significance level will be set at 5%. Stata
v11 and SPSS v21 will be used for the analysis.
15.Ethics: cases and controls will be requested to sign
the informed consent form. They will be explained
the general and specific ethical considerations of the
study with regard to the right to privacy, anonymity,
confidentiality, cancellation and information in
accordance with the principles of the Declaration of
Helsinki. The study has been approved by the
Clinical Research Ethics Committee of the Primary
Health Care University Research Institute (IDIAP)
Jordi Gol.
Discussion
The main limitations of this study are the memory bias
of patients and controls and/or their relatives, the time
elapsed between initial exposure to asbestos and the on-
set of ARD, and the different degrees of quality in the in-
formation obtained. Precision in recording the variables
that refer to time, place and lifestyles is the best tool to
minimise these limitations. Also, the health information
system that encompasses the entire population of the
study area is a powerful, effective tool to easily identify
possible cases and controls that will be made available to
the investigators.
ARD is an underreported, notifiable disease, and it is
rarely found as the underlying cause in death certificates.
In addition, it is an underreported work-related condition.
Other limitations are the refusal of the population to
participate in this type of study. Adequate training of the
professionals who participate in the study will circum-
vent most aforementioned limitations.
The case–control design of this study presents a major
advantage to investigate conditions with a low incidence.
The comparison of outcomes between groups underscoresthe health impact of continuous asbestos exposure in the
community.Conclusions
This study will describe the role of less known factors
involved in the protection and risk of ARD development
and progression. The study of comorbidities and lifestyle
of these patients, variables routinely collected in the
information systems of primary care, is of particular
interest.
The follow up of these patients in their own primary
care practices will enable the detection of ARD in previ-
ously unaffected patients and also of disease progression
in those patients previously diagnosed with some form
of ARD by means of modifications in their clinical
parameters.
Information on the general characteristics of patients
suffering from ARD and on the geographical clustering
of patients that originates from an intense and well
known source of exposure will improve our understand-
ing of the impact caused by asbestos on human health.
The set up of two cohorts for a case–control study will
facilitate time and survival comparisons. With the publica-
tion of this protocol, public health systems will have access
to a more precise tool in the fight against asbestosis.
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